Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial - Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)

NCT03007576 is registered in ClinicalTrials.gov with EMO Biomedicine Corporation as lead sponsor.

NCT NCT03007576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03007576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial - Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)
Lead sponsor
EMO Biomedicine Corporation
Phase
Phase 1
Overall status
Completed
Start date
August 1, 2017
Completion date
August 31, 2019
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis,knee